EA201270298A1 - Способ лечения злокачественной опухоли - Google Patents

Способ лечения злокачественной опухоли

Info

Publication number
EA201270298A1
EA201270298A1 EA201270298A EA201270298A EA201270298A1 EA 201270298 A1 EA201270298 A1 EA 201270298A1 EA 201270298 A EA201270298 A EA 201270298A EA 201270298 A EA201270298 A EA 201270298A EA 201270298 A1 EA201270298 A1 EA 201270298A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hla
treatment
malignant tumor
patient
tnxb
Prior art date
Application number
EA201270298A
Other languages
English (en)
Other versions
EA027959B1 (ru
Inventor
Нань Бин
Линда Перри Брили
Лаура Р. Бадд
Чарльз Дж. Кокс
Колин Ф. Спраггз
Original Assignee
Смитклайн Бичем (Корк) Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201270298(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смитклайн Бичем (Корк) Лтд. filed Critical Смитклайн Бичем (Корк) Лтд.
Publication of EA201270298A1 publication Critical patent/EA201270298A1/ru
Publication of EA027959B1 publication Critical patent/EA027959B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Предлагаются способы лечения человека от рака, включающие введение по меньшей мере одной дозы лапатиниба или его фармацевтически приемлемой соли или композиции пациенту, где указанный пациент не имеет один или несколько аллельных полиморфизмов, выбранных из группы из HLA-DQA1*0201, HLA-DQB1*0202 и/или HLA-DRB1*0701. Также пациенты свободны от генотипов в TNXB rs12153855 и/или rs17207923.
EA201270298A 2009-08-21 2010-08-20 Способ лечения рака с помощью лапатиниба EA027959B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23594709P 2009-08-21 2009-08-21
US30756910P 2010-02-24 2010-02-24
PCT/US2010/046142 WO2011022633A2 (en) 2009-08-21 2010-08-20 Method of threating cancer

Publications (2)

Publication Number Publication Date
EA201270298A1 true EA201270298A1 (ru) 2012-12-28
EA027959B1 EA027959B1 (ru) 2017-09-29

Family

ID=43607603

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270298A EA027959B1 (ru) 2009-08-21 2010-08-20 Способ лечения рака с помощью лапатиниба

Country Status (26)

Country Link
US (3) US20120156200A1 (ru)
EP (1) EP2467140B1 (ru)
JP (1) JP5876827B2 (ru)
KR (1) KR101781658B1 (ru)
CN (1) CN102770140B (ru)
AU (2) AU2010284092A1 (ru)
BR (1) BR112012003653A2 (ru)
CA (2) CA2771699C (ru)
CY (1) CY1118486T1 (ru)
DK (1) DK2467140T3 (ru)
EA (1) EA027959B1 (ru)
ES (1) ES2589377T3 (ru)
HR (1) HRP20161110T1 (ru)
HU (1) HUE029098T2 (ru)
IL (1) IL218230B (ru)
LT (1) LT2467140T (ru)
ME (1) ME02492B (ru)
MX (1) MX367580B (ru)
PL (1) PL2467140T3 (ru)
PT (1) PT2467140T (ru)
RS (1) RS55074B1 (ru)
SG (2) SG10201405039VA (ru)
SI (1) SI2467140T1 (ru)
SM (1) SMT201600296B (ru)
WO (1) WO2011022633A2 (ru)
ZA (1) ZA201201110B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505899A (ja) 2009-09-28 2013-02-21 チールー ファーマシューティカル カンパニー、リミテッド チロシンキナーゼ阻害剤として有用な４−（置換アニリノ）キナゾリン誘導体
CA2863287A1 (en) * 2012-01-31 2013-08-08 Smithkline Beecham (Cork) Limited Method of treating cancer
GB201403820D0 (en) * 2014-03-04 2014-04-16 Isis Innovation Assay
CN104293958B (zh) * 2014-10-16 2016-09-21 卫生部北京医院 一种预测强直性脊柱炎易感性的试剂盒和方法
BR112019012203A2 (pt) * 2016-12-14 2019-11-12 Beijing Genomics Inst At Shenzhen marcadores genéticos humanos associados à resposta para tratamentos que têm como alvo a toxina b de clostridium difficile

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
EP0897567A2 (en) 1996-04-19 1999-02-24 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CZ300945B6 (cs) 2000-06-30 2009-09-23 Glaxo Group Limited Zpusob prípravy 5-(6-chinazolinyl)-furan-2-karbaldehydu
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US7794960B2 (en) * 2004-06-04 2010-09-14 Glaxosmithkline Llc Predictive biomarkers in cancer therapy
JP2007117085A (ja) * 2005-09-28 2007-05-17 Genodive Pharma Kk 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法
JPWO2007099852A1 (ja) 2006-02-23 2009-07-16 国立大学法人金沢大学 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
US20090192101A1 (en) * 2006-11-22 2009-07-30 Mien-Chie Hung Cancer-specific promoters
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
WO2008112898A2 (en) * 2007-03-13 2008-09-18 The Children's Hospital Of Philadelphia Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes

Also Published As

Publication number Publication date
CN102770140A (zh) 2012-11-07
EP2467140A4 (en) 2013-11-06
AU2010284092A1 (en) 2012-03-08
SMT201600296B (it) 2016-11-10
CN102770140B (zh) 2017-06-23
US9539257B2 (en) 2017-01-10
KR20120059564A (ko) 2012-06-08
AU2014203270A1 (en) 2014-07-10
DK2467140T3 (en) 2016-09-05
CY1118486T1 (el) 2017-07-12
JP5876827B2 (ja) 2016-03-02
US20150231137A1 (en) 2015-08-20
WO2011022633A3 (en) 2012-12-27
PT2467140T (pt) 2016-08-30
ES2589377T3 (es) 2016-11-14
PL2467140T3 (pl) 2017-04-28
BR112012003653A2 (pt) 2016-03-22
WO2011022633A2 (en) 2011-02-24
MX367580B (es) 2019-08-27
JP2013502433A (ja) 2013-01-24
LT2467140T (lt) 2016-09-12
CA2771699A1 (en) 2011-02-24
CA3080511C (en) 2022-05-24
IL218230A0 (en) 2012-04-30
KR101781658B1 (ko) 2017-10-23
IL218230B (en) 2019-02-28
EP2467140B1 (en) 2016-06-01
SG178439A1 (en) 2012-04-27
HUE029098T2 (en) 2017-02-28
US10004742B2 (en) 2018-06-26
SI2467140T1 (sl) 2016-10-28
EA027959B1 (ru) 2017-09-29
AU2014203270B2 (en) 2016-06-16
CA2771699C (en) 2022-03-29
CA3080511A1 (en) 2011-02-24
US20120156200A1 (en) 2012-06-21
HRP20161110T1 (hr) 2016-11-04
RS55074B1 (sr) 2016-12-30
SG10201405039VA (en) 2014-10-30
EP2467140A2 (en) 2012-06-27
ZA201201110B (en) 2012-10-31
US20170065590A1 (en) 2017-03-09
ME02492B (me) 2017-02-20
MX2012002161A (es) 2012-07-17

Similar Documents

Publication Publication Date Title
IL189546A0 (en) Therapy for the treatment of disease
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
NO20054526L (no) Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen
HK1120441A1 (en) Drugs for treatment of ovarian cancer
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
EA200971053A1 (ru) Способы лечения кожных язв
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ703047A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE543492T1 (de) Behandlung von lungenkrebs
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
MX2022011171A (es) Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos.
RU2007129567A (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
NO20064609L (no) Behandling og forhindring av godartet brystsykdom med 4-hydroksytamoksifen
Boudewijns Indoor-photosensitivity and alopecia: 3 case reports

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM